Thrombocytosis as a prognostic marker in stage III and IV serous ovarian cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ObjectiveThrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer which is the most common clinical presentation of ovarian cancer. MethodsPlatelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for whom there were complete follow-up data on progression and survival. Survival and progression free survival of patients with normal platelet counts (150–350 ×109/L) was compared with that of patients with thrombocytosis (>350 ×109/L) by X2 and logrank tests. ResultsThe median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 273 ×109/L; range, 153–350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463 ×109/L; range, 354–631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a median survival of 43 months (range, 3–100). In the group of patients with thrombocytosis, 24 of the 39 patients had died with a median survival of 23 months (range, 4–79). In the entire group of 91 patients there was a statistically significant difference of the overall survival and progression-free survival between the two groups (logrank test P=0.02 and P=0.007, respectively). ConclusionIn this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had prognostic value regarding overall survival and progression-free survival.
Abstract
ObjectiveThrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer which is the most common clinical presentation of ovarian cancer. MethodsPlatelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for whom there were complete follow-up data on progression and survival. Survival and progression free survival of patients with normal platelet counts (150–350 ×109/L) was compared with that of patients with thrombocytosis (>350 ×109/L) by X2 and logrank tests. ResultsThe median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 273 ×109/L; range, 153–350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463 ×109/L; range, 354–631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a median survival of 43 months (range, 3–100). In the group of patients with thrombocytosis, 24 of the 39 patients had died with a median survival of 23 months (range, 4–79). In the entire group of 91 patients there was a statistically significant difference of the overall survival and progression-free survival between the two groups (logrank test P=0.02 and P=0.007, respectively). ConclusionIn this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had prognostic value regarding overall survival and progression-free survival.
참고문헌 (37)
- Bleeker JS, "Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies", Thrombosis, 2011, pp.536062~ (2011)
- Jelovac D, "Recent progress in the diagnosis and treatment of ovarian cancer", CA Cancer J Clin, 61, pp.183~203 (2011)
- Chan JK, "Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers", Gynecol Oncol, 109, pp.370~376 (2008)
- Fader AN, "Role of surgery in ovarian carcinoma", J Clin Oncol, 25, pp.2873~2883 (2007)
- Baldwin LA, "Ten-year relative survival for epithelial ovarian cancer", Obstet Gynecol, 120, pp.612~618 (2012)
- Mackay HJ, "Prognostic relevance of uncommon ovarian histology in women with stage III", IV epithelial ovarian cancer, 2010, pp.20, 945~952
- Emine Karabuk, "Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study", Journal of Gynecologic Oncology, 24(2), pp.160~166 (2013), 대한부인종양학회
- Stone RL, "Paraneoplastic thrombocytosis in ovarian cancer", N Engl J Med, 366, pp.610~618 (2012)
- Dawson B, "Basic & clinical biostatistics" (1994), Appleton & Lange
- Lawless JF, "Statistical models and methods for lifetime data" (1982), Wiley
- Levin J, "Thrombocytosis associated with malignant disease", Arch Intern Med, 114, pp.497~500 (1964)
- Taucher S, "Impact of pretreatment thrombocytosis on survival in primary breast cancer", Thromb Haemost, 89, pp.1098~1106 (2003)
- Stravodimou A, "Pretreatment thrombocytosis as a prognostic factor in metastatic breast cancer", Int J Breast Cancer, 2013, pp.289563~ (2013)
- Shimada H, "Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma", J Am Coll Surg, 198, pp.737~741 (2004)
- Hwang SG, "Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer", Eur J Surg Oncol, 38, pp.562~567 (2012)
- Brown KM, "Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas", Am J Surg, 189, pp.278~282 (2005)
- Symbas NP, "Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma", BJU Int, 86, pp.203~207 (2000)
- Hernandez E, "Poor prognosis associated with thrombocytosis in patients with cervical cancer", Cancer, 69, pp.2975~2977 (1992)
- Gungor T, "The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors", Arch Gynecol Obstet, 279, pp.53~56 (2009)
- Qiu J, "Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer", J Obstet Gynaecol Res, 38, pp.651~657 (2012)
- Li AJ, "The prognostic significance of thrombocytosis in epithelial ovarian carcinoma", Gynecol Oncol, 92, pp.211~214 (2004)
- Allensworth SK, "Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer", Gynecol Oncol, 130, pp.499~504 (2013)
- Timucin Mermer, "Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer", Journal of Gynecologic Oncology, 23(2), pp.86~90 (2012), 대한부인종양학회
- Paule B, "The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study", J Clin Pathol, 53, pp.388~390 (2000)
- Nakashima J, "Serum interleukin 6 as a prognostic factor in patients with prostate cancer", Clin Cancer Res, 6, pp.2702~2706 (2000)
- Benoy I, "Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients", Clin Breast Cancer, 2, pp.311~315 (2002)
- Buergy D, "Tumorplatelet interaction in solid tumors", Int J Cancer, 130, pp.2747~2760 (2012)
- Ho-Tin-Noe B, "How platelets safeguard vascular integrity", J Thromb Haemost, 9(Suppl 1), pp.56~65 (2011)
- Ho-Tin-Noe B, "Innate immune cells induce hemorrhage in tumors during thrombocytopenia", Am J Pathol, 175, pp.1699~1708 (2009)
- Gay LJ, "Contribution of platelets to tumour metastasis", Nat Rev Cancer, 11, pp.123~134 (2011)
- Battinelli EM, "Release of angiogenesis regulatory proteins from platelet alpha granules:modulation of physiologic and pathologic angiogenesis", Blood, 118, pp.1359~1369 (2011)
- Gunsilius E, "Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood", Oncology, 58, pp.169~174 (2000)
- Labelle M, "Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis", Cancer Cell, 20, pp.576~590 (2011)
- Kalluri R, "The basics of epithelial-mesenchymal transition", J Clin Invest, 119, pp.1420~1428 (2009)
- Niers TM, "Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker", PLoS One, 6, pp.e19873~ (2011)
- Heng DY, "Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy", Ann Oncol, 23, pp.1549~1555 (2012)
- Sato S, "Bevacizumab and ovarian cancer", Curr Opin Obstet Gynecol, 24, pp.8~13 (2012)